Iovance Biotherapeutics Inc (NASDAQ:IOVA) price on current trading day, fall -0.28% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.56.
A look at the stock’s price movement, the close in the last trading session was $3.57, moving within a range at $3.52 and $3.655. The beta value (5-Year monthly) was 0.929. Turning to its 52-week performance, $15.90 and $3.48 were the 52-week high and 52-week low respectively. Overall, IOVA moved -35.97% over the past month.
Iovance Biotherapeutics Inc’s market cap currently stands at around $1.17 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 83.36M for the company’s revenue for the quarter, with a low and high estimate of 74.65M and 102.8M respectively. The average forecast suggests up to a 11,558.67% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 448.99M, representing a 173.66% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IOVA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend IOVA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IOVA’s current price about -17.27% and -33.04% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 27.55, while 7-day volatility ratio is 6.32% and 7.37% in the 30-day chart. Further, Iovance Biotherapeutics Inc (IOVA) has a beta value of 1.02, and an average true range (ATR) of 0.33. Analysts have given the company’s stock an average 52-week price target of $11.5, forecast between a low of $6 and high of $17. Looking at the price targets, the low is -68.54% off current price level while to achieve the yearly target high, price needs to move -377.53%. Nonetheless, investors will most likely welcome a -223.03% jump to $11.5 which is the analysts’ median price.
If we refocus on Iovance Biotherapeutics Inc (NASDAQ:IOVA), historical trading data shows that trading volumes averaged 8.82 over the past 10 days and 9.60 million over the past 3 months. The company’s latest data on shares outstanding shows there are 305.25 million shares.
The 19.01% of Iovance Biotherapeutics Inc’s shares are in the hands of company insiders while institutional holders own 65.49% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 59.59 million on 2025-02-28, giving us a short ratio of 6.16. The data shows that as of 2025-02-28 short interest in Iovance Biotherapeutics Inc (IOVA) stood at 1994.0001 of shares outstanding, with shares short falling to 63.91 million registered in 2025-01-31. Current price change has pushed the stock -51.89% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IOVA stock continues to rise going into the next quarter.
